Fig 1.
Prescription volume and expenditures per patient by marketing authorization year in multisource markets.
Note: The figure shows utilization and expenditure of prescription medicines authorized between 1996 and 2014 prescribed in 2011–2014. Expenditure and prescriptions are expressed in million prescriptions. Prescription data was obtained from the CEGEDIM MEDIMED panel, 2011–2014. Data of first availability of a medicine in Germany by active ingredient was obtained from Arzneiverordnungsreport, 1997–2015. Prescription medicines approved earlier are excluded.
Table 1.
Conditional means at baseline and changes between first quarters of 2011 and 2014 in multisource markets.
Table 2.
Adoption bias adjusted regression results of changes in medicine use rates.
Table 3.
Decomposition of differential in prescription medicine use rates by brand name compared to generics.
Fig 2.
Decomposition of differential in use rates of brand name and generic medicines.
Note: The figure shows the utilization differential in medicines use rates of generic and brand name medicines decomposed by market structure, segment effects, interaction between market structure and segment effects (dashed line) and the difference (solid line) (Panel A) and the proportion of the explained and unexplained part of the decomposition (Panel B) by medicine use rate related outcomes by quarter from Q1/2011 to Q1/2014. In panel B, values larger than 150% were excluded from the figure. Prescription data was obtained from the CEGEDIM MEDIMED panel, 2011–2014. Expend: expenditure; Prescr: prescriptions, pat: patient.